functional precision medicine
2cureX a potential key player in precision cancer treatment
With the launch of IndiTreat last fall and the completed clinical study in colorectal cancer patients, 2cureX has attracted the attention of oncologists....
2cureX has appointed a new CEO
2cureX announced today that Fernando Andreu has been appointed...
2020: the year of 2cureX's IndiTreat launch
Although it has been a challenging year...
Strong Q3 for 2cureX culminates in IndiTreat launch
Last week, 2cureX's Q3 report was released and it...
2cureX launches IndiTreat
The ESMO Conference 2020 provides a virtual platform to...
2cureX board receives double supplement
As 2cureX approaches market launch...
Scandion Oncology and 2cureX receive grant from Eurostars
Resistance to antiestrogen drugs is a major problem in...
2cureX and partners receive EUR 1 million for automation of IndiTreat
During the week, 2cureX acquired German subsidiaries, together with...
2cureX advances according to plan towards IndiTreat launch
2cureX CBO pleased with new agreements
Danish 2cureX has announced
2cureX – pioneers in functional precision medicine
The level of innovation in the oncology field has taken significant steps forward...
2cureX comments on the ongoing cancer study
2cureX is testing its IndiTreat tool in a clinical...